Bill Warren advises clients on strategic intellectual property issues primarily in the life sciences sector, but also in a number of other industries. The majority of his practice focuses on patents related to biotechnology, medical device and pharmaceutical inventions. Bill prosecutes patents, counsels clients on patent validity and infringement issues and prepares product clearance opinions and development strategies. He also negotiates technology transfer licensing agreements and conducts intellectual property due diligence. Bill is chair of the firm’s biotechnology and life sciences team, and previously led Eversheds Sutherland (US)’s Intellectual Property Practice Group. He also protects trademarks and copyrights and, when necessary, participates in litigating intellectual property issues. In particular, he counsels various entities on Hatch-Waxman generic pharmaceutical and related biosimilars issues. For more than two decades, Bill has worked with clients ranging from multinational corporations, to early-stage entrepreneurial companies, to nonprofit university and science research centers. He is a frequent speaker and writer on developments in patent law affecting the life sciences industry.
389
A recent 11th Circuit case, Valley Drug Co. v. Geneva Pharmaceuticals, Inc., sheds light on the complex intersection of patent and antitrust law in the context of a settlement agreement between a name brand pharmaceutical manufacturer and two allegedly infringing generic manufacturers that (...)
19 avenue Jean Aicard
75011 Paris, France
106 West 32nd Street, Suite 149
New York, NY, 10001, USA
563 Chiswick High Road
W4 3AY London, UK